Which proteins are often targeted in breast cancer immunotherapy?

Which proteins are often targeted in breast cancer immunotherapy?

• A. ER and PR proteins
• B. HER2 protein and specific monoclonal antibodies
• C. BRAF and KRAS mutations
• D. CD20 antigen and T-cell receptors

Answer: (B)

The target for immunotherapy in breast cancer, particularly in certain subtypes, is primarily the HER2 protein along with specific monoclonal antibodies designed to engage the immune system in identifying and destroying cancer cells expressing this protein. HER2 is overexpressed in a subset of breast cancers, making it a significant target for therapies, such as trastuzumab (Herceptin) and other HER2-targeting medications. Monoclonal antibodies bind specifically to HER2, enhancing the immune response against tumors that present high levels of this protein. This targeted approach allows for a more refined therapeutic strategy compared to standard chemotherapy, which can affect both cancerous and healthy cells alike. Other options, while relevant to breast cancer treatment, do not focus specifically on immunotherapy strategies. For instance, ER and PR proteins are significant targets but are more related to hormonal therapy than immunotherapy. BRAF and KRAS mutations are associated with other cancers, such as melanoma or colorectal cancer, rather than breast cancer. The CD20 antigen and T-cell receptors pertain to hematological malignancies rather than solid tumors like breast cancer. Therefore, the targeting of the HER2 protein in breast cancer immunotherapy, especially through the utilization of monoclonal antibodies, is crucial for developing

The target for immunotherapy in breast cancer, particularly in certain subtypes, is primarily the HER2 protein along with specific monoclonal antibodies designed to engage the immune system in identifying and destroying cancer cells expressing this protein. HER2 is overexpressed in a subset of breast cancers, making it a significant target for therapies, such as trastuzumab (Herceptin) and other HER2-targeting medications.

Monoclonal antibodies bind specifically to HER2, enhancing the immune response against tumors that present high levels of this protein. This targeted approach allows for a more refined therapeutic strategy compared to standard chemotherapy, which can affect both cancerous and healthy cells alike.

Other options, while relevant to breast cancer treatment, do not focus specifically on immunotherapy strategies. For instance, ER and PR proteins are significant targets but are more related to hormonal therapy than immunotherapy. BRAF and KRAS mutations are associated with other cancers, such as melanoma or colorectal cancer, rather than breast cancer. The CD20 antigen and T-cell receptors pertain to hematological malignancies rather than solid tumors like breast cancer.

Therefore, the targeting of the HER2 protein in breast cancer immunotherapy, especially through the utilization of monoclonal antibodies, is crucial for developing